Limestone Investment Advisors’s AbbVie ABBV Stock Holding History

Limestone Investment Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$304K	Sell	1,400 -1,200	-46%	-$266K	0.02%	260
2025 Q4	$594K	Buy	+2,600	New	+$592K	0.06%	211
2025 Q3	–	Sell	-11,100	Closed	-$2.06M	–	525
2025 Q2	$2.06M	Buy	+11,100	New	+$2.06M	0.18%	116

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Limestone Investment Advisors's ABBV Position: Q1 2026 in Review

Limestone Investment Advisors opened a new position in AbbVie (ABBV) in Q1 2026: 1,340 shares worth $291K. The stake represents 0.02% of the portfolio and ranks #267 among its holdings.

4,078 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Limestone Investment Advisors held 1,340 shares of AbbVie worth $291K as of Q1 2026.
AbbVie was a new Limestone Investment Advisors position in Q1 2026.
AbbVie made up 0.02% of Limestone Investment Advisors's portfolio in Q1 2026, its #267 holding.
4,078 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Limestone Investment Advisors's 13F filing for Q1 2026, filed 15 May 2026.